ClinicalTrials.gg
CompletedNCT00938288Updated Oct 17, 2024

A Study of KW-3357 in Congenital Antithrombin Deficiency

A Phase 1 interventional study of KW-3357 in Congenital Antithrombin Deficiency, sponsored by Kyowa Kirin Co., Ltd.. Completed at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Thrombosis with a site in United Kingdom — 13 open to participants now, 16 under way, 4 of them phase 3. Thrombosis · United Kingdom.

Enrollment
33rd of 37
16 · median 131
Started
2009
with 3 others
Phase 1
4 of 57
none open now
Registered
9th of 57
by date

Among the 57 studies in Thrombosis with a site in United Kingdom, this one is the 33rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2009, is one of 4 in phase 1, and was the 9th registered.

Thrombosis

956 studies on the registry are indexed under Thrombosis; 172 are open to participants now.

Browse Thrombosis studies →

Open to participants now

13 of the 57 studies in Thrombosis with a site in United Kingdom are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 128 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 17 (13%) stop at 75 or younger; 21 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Thrombosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to determine the pharmacokinetics, safety and tolerability of KW-3357 in asymptomatic subjects with congenital antithrombin deficiency.

Read the detailed description

Patients with Congenital Antithrombin Deficiency are at increased risk of venous thrombosis and pulmonary embolism especially when undergoing certain high risk procedures. Antithrombin replacement therapy is often administered during these periods, with or without low molecular weight heparin. Prior to assessing the efficacy of KW-3357, a new recombinant human antithrombin, the present study will determine it's pharmacokinetics, safety and tolerability in subjects who have Congenital Antithrombin Deficiency but who are currently asymptomatic and not undergoing a high-risk procedure. Up to 16 evaluable subjects will be enrolled at multiple investigational sites over a period of approximately 7 months.

03

Conditions studied

  • Congenital Antithrombin Deficiency

Browse trials for

Keywords

  • Antithrombin
  • Thrombosis
  • Pharmacokinetics
  • Hereditary Antithrombin Deficiency
  • Congenital Antithrombin Deficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects at least 18 years of age with congenital Antithrombin deficiency (AT activity ≤60% of normal) in a stable condition without evidence of acute thromboembolic events
  • Signed IEC-approved Form
  • Subjects must not have received an infusion of Antithrombin for at least 14 days before Screening
  • Patients of must agree to follow accepted methods during the study

Exclusion criteria

Exclusion Criteria:

  • Subjects who are classified as morbidly obese (defined by the presence of a >40 kg/m2)
  • Subjects who have participated in a study with an drug within 30 days of Screening or within 5.5 times the elimination half-life of the investigational drug before Screening, whichever period is greater
  • Subjects with any medical history or current condition or physical findings, , or laboratory values which could interfere with the objectives of the study or the safety of the subject
  • Subjects using non-steroidal anti-inflammatories, fondaparinux sodium, dabigatran or rivaroxaban or who are expected to be treated with these drugs during the study
  • Subjects who have concomitant nephrotic syndrome
  • Female subjects who are pregnant or lactating
  • Subjects who are taking heparin, low molecular weight heparin and/or oral anticoagulants, with the exception of vitamin K antagonists (eg, warfarin)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    1

    Single group

    Drug: KW-3357

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the pharmacokinetic profile of a single dose (50 IU/kg) of KW 3357 in subjects with congenital AT deficiency

    Time frame: July 2011

Secondary outcomes

  1. To determine the safety and tolerability of a single dose (50 IU/kg) of KW-3357 in subjects with congenital AT deficiency

    Time frame: July 2011

07

Study locations

8 sites
  • Department of Haemotogy, Haemastasy, Oncology and Stem Cell Transplantation, Hannover Medical School
    Hannover, 30625, Germany
  • Center for Thrombosis and Haemostasis, Malmo University Hospital
    Malmö, SE-205 02, Sweden
  • Dept Obst Gyn/Section for Women and Child Health/Clinical Trial Unit, Karolinska University Hospital
    Stockholm, SE-171 76, Sweden
  • Treliske, Haematology Clinic, Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Bristol Haemophia Care Centre, Bristol Haemotology and Oncology Centre
    Bristol, BS2 8ED, United Kingdom
  • Department of Haemotology, Glasgow Royal Infirmary
    Glasgow, G4 0SF, United Kingdom
  • Kings College, Dept of Haematology, Lupus & Pathology Guy's and St Thomas Trust, St Thomas Hospital, Ctr for Haemostasis and Thrombosis (the Haemophia Reference Ctr)
    London, SE1 7EH, United Kingdom
  • University College London Hospital NHS Trust
    London, WIT 4EU, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Dec 2010 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2009
First posted
Jul 13, 2009
Start
Apr 2009
Primary completionActual
Dec 22, 2010
CompletionActual
Apr 2011
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00938288
Collaborators
Kyowa Hakko Kirin UK, Ltd.
Responsible party
Sponsor
First posted
Jul 13, 2009
Start date
Apr 2009
Primary completion
Dec 22, 2010
Completion
Apr 2011
Last update
Oct 17, 2024

Study contacts

Beverley Hunt, FRCP, FRCPath MD
principal investigator · St Thomas' Hospital, London, UK

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antithrombin alfa

Start the discussion